Synopsis: Aurobindo Pharma’s wholly owned subsidiary, Apitoria Pharma, will acquire an 80 percent stake in A1 Biochem Group’s Contract Research Services business for an enterprise value of USD 17 million. The acquisition expands Aurobindo’s presence beyond API manufacturing into integrated Contract Research, Development and Manufacturing (CRDMO) services while strengthening its global pharmaceutical innovation platform.
Shares of Aurobindo Pharma Limited are likely to remain in focus after the company announced that its wholly owned subsidiary, Apitoria Pharma Private Limited, has approved the acquisition of 80 percent ownership in the Contract Research Services (CRO) business of A1 Biochem Group at an enterprise value of USD 17 million on a debt-free and cash-free basis.
Aurobindo Pharma Limited has a market capitalization of approximately Rs. 88834crore. The company’s shares were trading at Rs.1527.20 apiece on the stock exchange. It touched a 52-week high of Rs. 1636.80 and a 52-week low of Rs. 1016.60.
According to the company’s exchange filing, Apitoria Pharma will acquire an 80 percent stake in A1 Biochem Labs (India) Private Limited, while A1 Biochem Labs (India) will subsequently acquire 100 percent ownership of A1 Biochem Labs LLC, USA, along with the CRO business of A1 Biochem Research (India) Private Limited. The transaction values the business at USD 17 million, with Aurobindo investing USD 13.6 million for its 80 percent ownership. The acquisition is expected to be completed within 90 to 120 days, subject to customary approvals.
The acquisition marks an important strategic step in Aurobindo Pharma’s evolution from being primarily an Active Pharmaceutical Ingredients (API) manufacturer to becoming an integrated Contract Research, Development and Manufacturing Organisation (CRDMO). While Apitoria already operates large-scale regulatory-compliant API manufacturing facilities, acquiring front-end research and development capabilities enables the company to offer customers end-to-end pharmaceutical development services—from early-stage research through commercial manufacturing.
The acquired A1 Biochem Group brings established capabilities in custom synthesis, medicinal chemistry, route scouting, analytical development and rapid process scale-up services, serving pharmaceutical companies, biotechnology firms and academic institutions, primarily in the United States. The business generated a turnover of Rs. 102.44 crore (INR 1,024.42 million) with an EBITDA of Rs. 46.55 crore (INR 465.46 million) during FY26 and operates scientific laboratories in North Carolina, USA, and Hyderabad, India, supported by over 90 scientists, 50+ fume hoods, a client base of more than 50 customers and a track record of completing over 800 projects.
The acquisition is expected to strengthen Aurobindo’s competitive position in the rapidly growing global CRDMO market, where pharmaceutical companies increasingly outsource drug discovery, process development and manufacturing to specialised partners. By combining A1 Biochem’s research expertise with Apitoria’s large-scale manufacturing infrastructure, Aurobindo can participate across a larger portion of the pharmaceutical value chain, improve customer retention through longer-term engagements and diversify revenue streams beyond conventional API manufacturing.
For investors, the transaction represents a strategic growth initiative rather than a short-term earnings trigger. The acquisition expands Aurobindo’s presence in high-value pharmaceutical research services, enhances its global capabilities and strengthens its exposure to innovation-driven outsourcing opportunities. As global pharmaceutical companies continue to increase spending on outsourced research and development, the integrated CRDMO platform could support higher-margin business opportunities and contribute to sustainable long-term growth.
Aurobindo Pharma Limited is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals and related services. The company has a diversified global presence across formulations, injectables, biosimilars and APIs, supplying products to more than 150 countries while serving regulated markets including the United States, Europe and emerging economies.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing.
